Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Medtronic/Neurex Corporation

This article was originally published in The Gray Sheet

Executive Summary

Medtronic/Neurex Corporation: Neurex secures an $8 mil. convertible loan from Medtronic under the terms of an April 1994 agreement between the two firms. The $8 mil. will convert to common stock after Neurex "has raised a mutually agreed amount of equity financing," the firms say. Medtronic and Neurex entered an agreement in April 1994 to commercialize Neurex' SNX-111 neuron-specific calcium channel blocker for chronic neuropathic pain via direct administration with Medtronic's SynchroMed implantable programmable drug pump ("The Gray Sheet" May 2, 1994, In Brief). The loan is "aimed at significantly strengthening Neurex' financial position," the companies say...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel